Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Acetylcysteine zidrimer by Orpheris for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData,...
Acetylcysteine zidrimer by Orpheris for Alzheimer's Disease: Likelihood of Approval
Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase...
Acetylcysteine zidrimer by Orpheris for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)): Likelihood of Approval
Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase II for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)). According to...
Acetylcysteine zidrimer by Orpheris for Parkinson's Disease: Likelihood of Approval
Acetylcysteine zidrimer is under clinical development by Orpheris and currently in Phase I for Parkinson's Disease. According to GlobalData, Phase...